A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

NCT05089019 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Selpercatinib

Sponsor

Loxo Oncology, Inc.

Collaborators

[object Object]